---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-026868"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:49:00.474416+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TScan Q4 net loss $19.6M; all 8 TSC-100/101 patients relapse-free

## Summary
- Q4 revenue $7.2M (up from $3.1M YoY); full-year revenue $21.0M. R&D expenses $22.4M Q4, $88.2M full year.
- Cash $192M as of Dec 31, 2023; cash runway into 2026.
- Phase 1 heme data: 8/8 treatment-arm patients relapse-free; one high-risk MDS patient reached 1 year post-TSC-101.
- FDA cleared INDs for TSC-201-B0702 (MAGE-C2) and TSC-204-A0101 (MAGE-A1); solid tumor trial enrolling.
- Appointed Jason Amello as CFO, Justin McCue as CTO; promoted several executives.

## SEC filing metadata
- accession: 0000950170-24-026868
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000095017024026868/0000950170-24-026868-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000095017024026868/tcrx-20240306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-026868
- JSON: https://secwatch.observer/filing/0000950170-24-026868.json
- Plain text: https://secwatch.observer/filing/0000950170-24-026868.txt

## Key facts
- Earnings Releases
  TScan Therapeutics, Inc. reported financial results for the three months and full year ended December 31, 2023.
  - Period: the three months and full year ended December 31, 2023
  - Result: reported results
  source text: TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results for the three months and full year ended December 31, 2023, and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000095017024026868/0000950170-24-026868-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.